Candidate biomarkers for idiopathic multicentric Castleman disease-Reference-Cited by-同舟云学术

Candidate biomarkers for idiopathic multicentric Castleman disease

Published:2022 Issue:2 Volume:62 Page:85-90
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Sumiyoshi Remi¹,Koga Tomohiro²,Kawakami Atsushi¹

Affiliation:

1. Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan,

2. Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/62/2/62_22010/_pdf

Reference31 articles.

1. 1 Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956; 9: 822-830.

2. 2 Bartoli E, Massarelli G, Soggia G, Tanda F. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol. 1980; 73: 423-426.

3. 3 Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki. 2010; 51: 320-325 [in Japanese].

4. 4 Yoshizaki K, Matsuda T, Nishimoto N et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989; 74: 1360-1367.

5. 5 Koga T, Sumiyoshi R, Kawakami A, Yoshizaki K. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman’s disease. Mod Rheumatol. 2019; 29: 302-305.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes;Frontiers in Immunology;2024-09-10

2. A hypothesis on treatment strategy of severe multicentric Castleman disease with continuous renal replacement therapy;Journal of Cellular and Molecular Medicine;2024-09

3. TAFRO Syndrome and COVID-19;Biomedicines;2024-06-11

4. Overview of Research Status in Castleman Disease;Clinical Lymphoma Myeloma and Leukemia;2024-06

5. Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy;Blood Vessels, Thrombosis & Hemostasis;2024-06